Naproxen
- Generic Name
- Naproxen
- Brand Names
- Aleve, Aleve PM, Aleve-D, Anaprox, Naprelan, Naprosyn, Sallus, Sudafed Sinus & Pain, Treximet, Vimovo
- Drug Type
- Small Molecule
- Chemical Formula
- C14H14O3
- CAS Number
- 22204-53-1
- Unique Ingredient Identifier
- 57Y76R9ATQ
- Background
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, nap...
- Indication
Naproxen is indicated for the management of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, polyarticular juvenile idiopathic arthritis, tendinitis, bursitis, acute gout, primary dysmenorrhea, and for the relief of mild to moderate pain. Further, it is first-line therapy for osteoarthritis, acute gouty arthritis, dysmenorrhea, and musculoskelet...
- Associated Conditions
- Acute Gouty Arthritis, Acute Migraine, Ankylosing Spondylitis (AS), Back pain, Bursitis, Extra-Articular Rheumatism, Fever, Flu caused by Influenza, Headache, Juvenile Idiopathic Arthritis (JIA), Menstrual Distress (Dysmenorrhea), Migraine, Muscle Spasms, Nasal Congestion, Osteoarthritis (OA), Pain, Post Traumatic Pain, Postoperative pain, Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Seasonal Allergic Rhinitis, Sinusitis, Tendinitis, Toothache, Articular inflammation
- Associated Therapies
- -
Efficacy of Multimodal Analgesia Following Hip Arthroscopy
- Conditions
- Interventions
- First Posted Date
- 2017-11-22
- Last Posted Date
- 2021-10-15
- Lead Sponsor
- Western University, Canada
- Target Recruit Count
- 100
- Registration Number
- NCT03351439
- Locations
- 🇨🇦
Fowler Kennedy Sport Medicine Clinic, London, Ontario, Canada
To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Antibe Therapeutics Inc.
- Target Recruit Count
- 258
- Registration Number
- NCT03291418
- Locations
- 🇨🇦
Topstone Clinical Research, Toronto, Ontario, Canada
Study to Evaluate the Pharmacokinetics and Pharmacodynamics of JMI-001
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2017-06-12
- Lead Sponsor
- Sen-Jam Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT03183297
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
- Conditions
- Interventions
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 3307
- Registration Number
- NCT03161093
- Locations
- 🇺🇸
Pacific Arthritis Care Center, Los Angeles, California, United States
🇺🇸Lynn Institute of the Rockies, Colorado Springs, Colorado, United States
🇺🇸Panorama Orthopedics & Spine Center, Golden, Colorado, United States
Pharmacogenetic and Pharmacokinetics of Naproxen and Associated Naproxen-esomeprazole
- Conditions
- Interventions
- First Posted Date
- 2017-03-27
- Last Posted Date
- 2020-11-03
- Lead Sponsor
- University of Sao Paulo
- Target Recruit Count
- 8
- Registration Number
- NCT03092193
- Locations
- 🇧🇷
Bauru School of Dentistry/USP, Bauru, São Paulo, Brazil
A Study to Evaluate the Analgesic Efficacy and Safety of V120083 in Subjects With Osteoarthritis (OA) of the Knee
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2019-02-12
- Lead Sponsor
- Purdue Pharma LP
- Target Recruit Count
- 291
- Registration Number
- NCT03028870
- Locations
- 🇺🇸
New Horizon Research Center, Miami, Florida, United States
🇺🇸New Horizons Clinical Research, Cincinnati, Ohio, United States
🇺🇸Diagnostics Research Group, San Antonio, Texas, United States
Placebo In Chronic Back Pain (Phase 2)
- Conditions
- Interventions
- First Posted Date
- 2016-12-08
- Last Posted Date
- 2022-11-07
- Lead Sponsor
- Apkar Apkarian
- Target Recruit Count
- 94
- Registration Number
- NCT02986334
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
Comparison of Different Analgesia Drug Regimens for Pain Control During ESWL for Renal Stones
- Conditions
- Interventions
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2016-06-01
- Lead Sponsor
- Shifa International Hospital
- Target Recruit Count
- 135
- Registration Number
- NCT02786446
Efficacy of Intrauterine Lidocaine and Naproxen for Pain Control With Intrauterine Device Insertion
- Conditions
- Interventions
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2018-11-08
- Lead Sponsor
- Walter Reed National Military Medical Center
- Target Recruit Count
- 160
- Registration Number
- NCT02769247
- Locations
- 🇺🇸
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
A Proof-of-Concept Study Assessing NEO6860 in Osteoarthritis Pain
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2017-03-13
- Lead Sponsor
- Neomed Institute
- Target Recruit Count
- 54
- Registration Number
- NCT02712957
- Locations
- 🇨🇦
Diex Recherche Montreal Inc, Montreal, Quebec, Canada
🇨🇦Algorithme Pharma, Montreal, Quebec, Canada
🇨🇦Diex Recherche Sherbrooke Inc, Sherbrooke, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.